Financial health
- The company is unprofitable; at its current free-cash-flow burn it has roughly 1.8 years of cash runway.
AMLX Financials Amylyx Pharmaceuticals, Inc.
5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0 | -$145M | — | — | -47.4% | -43.5% | -$123M | — | $227M |
| 2024 | $87M | -$302M | 93.2% | -360.2% | -183.1% | -155.8% | -$168M | — | $77M |
| 2023 | $381M | $49M | 93.3% | 10.2% | 11.4% | 9.5% | $11M | — | $170M |
| 2022 | $22M | -$198M | 86.5% | -905.7% | -58.2% | -50.7% | -$182M | — | $63M |
| 2021 | — | -$88M | — | — | 58.2% | -83.3% | -$75M | — | $50M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$43M | — | — | -18.2% | -16.4% | — | — | $49M |
| Mar '26 | — | -$41M | — | — | -15.1% | -14.1% | — | — | $229M |
| Dec '25 | $0 | -$33M | — | — | -10.8% | -9.9% | -$28M | — | $227M |
| Sep '25 | $0 | -$34M | — | — | -10.4% | -9.5% | -$30M | — | $225M |
| Jun '25 | $0 | -$41M | — | — | -24.7% | -21.3% | -$25M | — | $58M |
| Mar '25 | $0 | -$36M | — | — | -17.8% | -16.3% | -$40M | — | $60M |
| Dec '24 | -$665000 | -$38M | 100.0% | 6113.4% | -22.8% | -19.4% | -$59M | — | $77M |
| Sep '24 | $416000 | -$73M | 100.0% | -18187.7% | -37.1% | -29.0% | -$42M | — | $72M |
| Jun '24 | -$1M | -$73M | 100.8% | 7457.1% | -27.8% | -21.9% | -$67M | — | $75M |
| Mar '24 | $89M | -$119M | 93.3% | -137.8% | -36.6% | -28.5% | -$556000 | — | $171M |
| Dec '23 | $108M | $5M | 91.4% | 1.8% | 1.1% | 0.9% | $13M | — | $170M |
| Sep '23 | $103M | $21M | 94.9% | 18.2% | 5.0% | 4.5% | -$6M | — | $135M |
| Jun '23 | $98M | $22M | 94.3% | 20.6% | 5.7% | 4.9% | $8M | — | $248M |
| Mar '23 | $71M | $2M | 92.6% | -2.9% | 0.4% | 0.4% | -$5M | — | $115M |
| Dec '22 | $22M | -$43M | 87.1% | -203.8% | -12.5% | -10.9% | -$50M | — | $63M |
| Sep '22 | $345000 | -$54M | 50.1% | -15849.6% | -37.3% | -29.6% | -$44M | — | $108M |
| Jun '22 | — | -$54M | — | — | -28.0% | -24.0% | -$48M | — | $67M |
| Mar '22 | — | -$48M | — | — | -19.9% | -17.4% | -$41M | — | $110M |
| Dec '21 | — | -$28M | — | — | 18.8% | -26.8% | -$28M | — | $50M |
| Sep '21 | — | -$23M | — | — | 18.7% | — | -$21M | — | — |
Valuation over time
How the market has priced AMLX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 36.2× (Jan '24) to 12.5× (Nov '24).
- The price-to-sales ratio has fallen from 147.0× (Mar '23) to 19.1× (Nov '25).
P/E
P/S
Frequently asked questions
Is AMLX growing its revenue and profit?
See the revenue and net-income charts above for Amylyx Pharmaceuticals, Inc.'s multi-year trend.
How much debt does AMLX have?
As of FY2025, Amylyx Pharmaceuticals, Inc. reported — of total debt against $227M of cash.
What is AMLX's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
What is AMLX's P/E ratio?
As of Sep '26, Amylyx Pharmaceuticals, Inc. traded at a price-to-earnings ratio of about 12.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.